Get started
Author

Takeyuki Nagashima

Observed names: Nagashima, T., T Nagashima, T. Nagashima, Takeyuki NAGASHIMA
ORCID: 0000-0002-9496-3259
Observed ORCID: 0000-0002-9496-3259
OpenAlex ID: A5112160732
Discovery of Novel Forkhead Box O1 Inhibitors for Treating Type 2 Diabetes: Improvement of Fasting Glycemia in Diabetic db/db Mice
2010 · Takeyuki Nagashima, Nobuharu Shigematsu, et al. · Molecular Pharmacology · 278
Efficient delivery of siRNA using dendritic poly(l-lysine) for loss-of-function analysis
2007 · Yusuke Inoue, Ryosuke Kurihara, et al. · Journal of Controlled Release · 115
Discovery of KRAS(G12D) selective degrader ASP3082
2025 · Tomohiro Yoshinari, Takeyuki Nagashima, et al. · Communications Chemistry · 72
PDF
ASP3082, a First-in-class novel KRAS G12D degrader, exhibits remarkable anti-tumor activity in KRAS G12D mutated cancer models
2022 · T. Nagashima, K. Inamura, et al. · European Journal of Cancer · 57
PDF
Diclofenac, a non-steroidal anti-inflammatory drug, suppresses apoptosis induced by endoplasmic reticulum stresses by inhibiting caspase signaling
2006 · Takao Yamazaki, Masakazu Muramoto, et al. · Neuropharmacology · 53
Effects of the novel Foxo1 inhibitor AS1708727 on plasma glucose and triglyceride levels in diabetic db/db mice
2010 · Hirotsugu Tanaka, Takeyuki Nagashima, et al. · European Journal of Pharmacology · 39
In vivo selective expansion of gene-modified hematopoietic cells in a nonhuman primate model
2002 · Y Hanazono, T Nagashima, et al. · Gene Therapy · 35
Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models
2021 · Ayako Nakayama, Takeyuki Nagashima, et al. · British Journal of Cancer · 24
Differences in gene expression profile among SH‐SY5Y neuroblastoma subclones with different neurite outgrowth responses to nerve growth factor
2005 · Tomoya Oe, Takeshi Sasayama, et al. · Journal of Neurochemistry · 24
Abstract 5735: Novel KRAS G12D degrader ASP3082 demonstrates in vivo, dose-dependent KRAS degradation, KRAS pathway inhibition, and antitumor efficacy in multiple KRAS G12D-mutated cancer models
2023 · Takeyuki Nagashima, Tomohiro Yoshinari, et al. · Cancer Research · 22
Development of a potent and orally active activator of adenosine monophosphate-activated protein kinase (AMPK), ASP4132, as a clinical candidate for the treatment of human cancer
2020 · Kazuyuki Kuramoto, Hiroyoshi Yamada, et al. · Bioorganic & Medicinal Chemistry · 15
Mass-tag technology for monitoring of protein kinase activity using mass spectrometry
2004 · Tatsuhiko Sonoda, Syuhei Shigaki, et al. · Bioorganic & Medicinal Chemistry Letters · 15
Introduction of the green fluorescent protein gene into hematopoietic stem cells results in prolonged discrepancy of in vivo transduction levels between bone marrow progenitors and peripheral blood cells in nonhuman primates
2002 · Yutaka Hanazono, Keiji Terao, et al. · The Journal of Gene Medicine · 15
Discovery and biological evaluation of 1-{2,7-diazaspiro[3.5]nonan-2-yl}prop-2-en-1-one derivatives as covalent inhibitors of KRAS G12C with favorable metabolic stability and anti-tumor activity
2022 · Tomoyoshi Imaizumi, Michinori Akaiwa, et al. · Bioorganic & Medicinal Chemistry · 14
Collection and analysis of hematopoietic progenitor cells from cynomolgus macaques (Macaca fascicularis): Assessment of cross‐reacting monoclonal antibodies
2003 · Hiroaki Shibata, Yutaka Hanazono, et al. · American Journal of Primatology · 14
Virtual clinical trial simulations for a novel KRASG12C inhibitor (ASP2453) in non‐small cell lung cancer
2021 · Hiroyuki Sayama, Diana Marcantonio, et al. · CPT Pharmacometrics & Systems Pharmacology · 13
PDF
High-Level in Vivo Gene Marking after Gene-Modified Autologous Hematopoietic Stem Cell Transplantation without Marrow Conditioning in Nonhuman Primates
2004 · Kyoji Ueda, Yutaka Hanazono, et al. · Molecular Therapy · 13
CyclinB2 and BIRC5 genes as surrogate biomarkers for neurite outgrowth in SH-SY5Y subclonal cells
2006 · Tomoya Oe, Takeyuki Nagashima, et al. · Neuropharmacology · 11
In vivo expansion of gene‐modified hematopoietic cells by a novel selective amplifier gene utilizing the erythropoietin receptor as a molecular switch
2003 · Takeyuki Nagashima, Yasuji Ueda, et al. · The Journal of Gene Medicine · 10
Safe and efficient methods of autologous hematopoietic stem cell transplantation for biomedical research in cynomolgus monkeys.
2002 · Naohide Ageyama, Yutaka Hanazono, et al. · PubMed · 10
Enhanced Antitumor Immunity by ASP1570, a Novel Diacylglycerol Kinase ζ Inhibitor, Offers a Potential Novel Immunotherapy for Treating Cancer
2025 · Osamu Ikeda, Aya Kikuchi, et al. · Molecular Cancer Therapeutics · 7
Discovery of ASP6918, a KRAS G12C inhibitor: Synthesis and structure–activity relationships of 1-{2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one derivatives as covalent inhibitors with good potency and oral activity for the treatment of solid tumors
2023 · Tomoyoshi Imaizumi, Itsuro Shimada, et al. · Bioorganic & Medicinal Chemistry · 7
Novel Indirect AMP-Activated Protein Kinase Activators: Identification of a Second-Generation Clinical Candidate with Improved Physicochemical Properties and Reduced hERG Inhibitory Activity
2020 · Kazuyuki Kuramoto, Yuki Sawada, et al. · Chemical and Pharmaceutical Bulletin · 5
PDF
A new method for evaluation of intracellular protein kinase signals using mass spectrometry
2006 · Syuhei Shigaki, Tatsuhiko Sonoda, et al. · Science and Technology of Advanced Materials · 5
PDF
Prevention of Immune Responses to Human Erythropoietin in Cynomologus Monkeys (Macaca fascicularis)
2006 · Naohide AGEYAMA, Yutaka HANAZONO, et al. · Journal of Veterinary Medical Science · 5
PDF
Works count: 48
Citation count: 896
H-index: 14
I10-index: 20
Year
Topic
Type